DTL
VERV

Dynamic Technology Lab’s Verve Therapeutics VERV Stock Holding History

Dynamic Technology Lab’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-23,097
Closed -$113K – 1384
2024
Q2 		$113K Buy
+23,097
New +$145K 0.01% 846
2023
Q3 		– Sell
-11,051
Closed -$207K – 1361
2023
Q2 		$207K Buy
+11,051
New +$184K 0.03% 822

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Dynamic Technology Lab's VERV Position: Q3 2024 in Review

Dynamic Technology Lab sold out of Verve Therapeutics (VERV) in Q3 2024, closing a stake of 23,097 shares — an estimated $113K sold.

Dynamic Technology Lab first reported a position in VERV in Q2 2023 and held it in 2 quarters. The position peaked at $207K in Q2 2023. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

  • Dynamic Technology Lab reported no remaining Verve Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Dynamic Technology Lab sold 23,097 Verve Therapeutics shares in Q3 2024, an estimated $113K.
  • Dynamic Technology Lab first reported a position in Verve Therapeutics in Q2 2023 and held it in 2 quarters.
  • Dynamic Technology Lab's Verve Therapeutics position peaked at $207K in Q2 2023.
  • 174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on Dynamic Technology Lab's 13F filing for Q3 2024, filed 13 Nov 2024.